{
    "id": "correct_subsidiary_00047_1",
    "rank": 33,
    "data": {
        "url": "https://adisinsight.springer.com/drugs/800017293",
        "read_more_link": "",
        "language": "en",
        "title": "Stiefel Laboratories",
        "top_image": "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/ajax_loader.gif",
        "meta_img": "",
        "images": [
            "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/ajax_loader.gif",
            "https://adisinsight.springer.com/assets/images/adisinsight_logo.svg",
            "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/loading_search.gif",
            "https://adisinsight.springer.com/static/private/chemicalimage/thumb/4/800017293.png",
            "https://adisinsight.springer.com/static/private/chemicalimage/png/4/800017293.png",
            "https://adisinsight.springer.com/assets/images/icons/springer.svg",
            "https://adisinsight.springer.com/assets/images/icons/springernature.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Clindamycin foam - Stiefel Laboratories",
            "1 Clindamycin phosphate foam",
            "1 Evoclin foam",
            "Evoclin",
            "Protein synthesis inhibitors",
            "Antibacterials",
            "Lincosamides",
            "Small molecules",
            "Stiefel Laboratories",
            "Acne vulgaris"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Stiefel Laboratories (formerly Connetics Corporation) is developing a foam formulation of 1% clindamycin [1% clindamycin phosphate foam, Evoclin™, Actiza™] for",
        "meta_lang": "en",
        "meta_favicon": "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "http://adisinsight.springer.com",
        "text": "Subscriber content\n\nYou need to be a logged in subscriber to view this content.\n\nIf your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.\n\nIP authentication when working within your organization’s network.\n\nLogin with username/password or try access via your institution\n\nPersisted access using your organization’s identifier stored in your user browser for 90 days.\n\nContact us at AsktheExpert.AdisInsight@springer.com for assistance.\n\nIf your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following."
    }
}